599 related articles for article (PubMed ID: 19652878)
1. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
2. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis.
Pannell R; Kung W; Gurewich V
J Thromb Haemost; 2007 May; 5(5):1047-54. PubMed ID: 17459007
[TBL] [Abstract][Full Text] [Related]
3. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.
Tomasi S; Sarmientos P; Giorda G; Gurewich V; Vercelli A
PLoS One; 2011; 6(7):e21999. PubMed ID: 21779364
[TBL] [Abstract][Full Text] [Related]
4. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.
Pannell R; Li S; Gurewich V
PLoS One; 2015; 10(3):e0122018. PubMed ID: 25811605
[TBL] [Abstract][Full Text] [Related]
5. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
8. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
Pannell R; Li S; Gurewich V
J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
[TBL] [Abstract][Full Text] [Related]
9. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.
Weitz JI; Leslie B; Hirsh J; Klement P
J Clin Invest; 1993 Apr; 91(4):1343-50. PubMed ID: 7682569
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the murine plasma fibrinolytic system.
Lijnen HR; van Hoef B; Beelen V; Collen D
Eur J Biochem; 1994 Sep; 224(3):863-71. PubMed ID: 7523120
[TBL] [Abstract][Full Text] [Related]
11. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.
Gurewich V; Pannell R; Simmons-Byrd A; Sarmientos P; Liu JN; Badylak SF
J Thromb Haemost; 2006 Jul; 4(7):1559-65. PubMed ID: 16839354
[TBL] [Abstract][Full Text] [Related]
12. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
13. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
[TBL] [Abstract][Full Text] [Related]
15. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
Graham DA; Huang TC; Keyt BA; Alevriadou BR
Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
[TBL] [Abstract][Full Text] [Related]
16. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
Sugiyama N; Iwamoto M; Abiko Y
Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
[TBL] [Abstract][Full Text] [Related]
17. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
18. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
19. Synergistic fibrinolysis: The combined effects of tissue plasminogen activator and recombinant staphylokinase in vitro.
Aisina R; Mukhametova L; Varfolomeyev S
Biochim Biophys Acta; 2016 Apr; 1860(4):629-35. PubMed ID: 26723174
[TBL] [Abstract][Full Text] [Related]
20. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
